Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusinessStocks

Strides Pharma share price gains on USFDA approval

The company has 124 cumulative ANDA filings with USFDA, of which 87 have been approved and 37 are waiting approval.

July 09, 2020 / 09:41 AM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Strides Pharma Science share price added over 1 percent in the early trade on July 9 after the company received United States Food & Drug Administration (USFDA) approval for a pain-relieving drug.

Company's step‐down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules, 50 mg/325 mg/40 mg/30 mg from the US drug regulator, a release said.

The product is a generic version of Fioricet with Codeine Capsules, 50 mg/325 mg/40 mg/30 mg, of Teva Branded Pharmaceutical Product R&D, Inc.

Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules is indicated for the relief of the symptom complex of tension (or muscle contraction) headache.

The US market for Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules is approximately $10 million, as per the IQVIA MAT May 2020 data.

The product will be marketed by Strides Pharma Inc in the US.

The company has 124 cumulative ANDA filings with USFDA of which 87 have been approved and 37 are pending.

At 0925 hours, Strides Pharma Science was quoting at Rs 415.10, up Rs 3.75, or 0.91 percent on the BSE.

Moneycontrol News
first published: Jul 9, 2020 09:41 am

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347